Abstract
Integrating artificial intelligence (AI) and machine learning (ML) into pancreatic cancer care has the potential to revolutionize early prediction, detection, and staging, significantly improving patient outcomes. This commentary explores the importance of seamlessly incorporating AI technologies into clinical workflows. AI can enhance the interpretation of medical images and analyze electronic health records for risk identification and prediction. By using sensors on everyday devices, individuals can contribute to comprehensive personal health records, enabling real-time differential diagnoses during patient encounters. However, the adoption of AI in clinical medicine remains limited, primarily due to challenges in data privacy, algorithm accuracy, and regulatory frameworks. To address these challenges, incentivizing the development of interoperable and unbiased AI technologies through regulatory and payment frameworks is crucial. Greater reimbursements for AI devices demonstrating broad applicability and mitigating bias can motivate developers to create more inclusive tools. Collaboration among AI developers, radiologists, oncologists, surgeons, and other health care professionals is essential to create user-friendly systems that enhance clinical practice. By overcoming these obstacles, AI can provide actionable insights, supporting clinicians in delivering personalized and effective care, and ultimately transforming the landscape of precision oncology.
Get full access to this article
View all access options for this article.